HADHB (P55084) variants and mutations
HADHB (also known as P55084) is a human protein-coding gene encoding a trifunctional enzyme subunit beta, mitochondrial protein. It provides two enzymatic activities of the mitochondrial trifunctional complex required for long-chain fatty-acid beta-oxidation. Biallelic pathogenic variants can cause mitochondrial trifunctional-protein deficiency or long-chain 3-hydroxyacyl-CoA dehydrogenase-related disease, with cardiomyopathy, hypoglycemia, neuropathy, or rhabdomyolysis. This analysis covers 725 HADHB variants and mutations. Of these, 82% have computational variant effect predictions. Disease context includes mitochondrial trifunctional protein deficiency 2, mitochondrial trifunctional protein deficiency, and mitochondrial trifunctional protein deficiency 1. Example HADHB variants include M1V, p.Met1 Thr2insAla, and p.Thr2dup.
Variant analysis overview
- Gene: HADHB
- Protein: P55084
- UniProt accession: P55084
- Organism: Homo sapiens
- Variants analyzed: 725
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 555 unspecified-consequence records; 3 in-frame insertions; 20 frameshift variants; 92 missense variants; 1 protein altering variant; 44 synonymous variants; 3 stop-gained variants; 4 splice-region variants; 1 in-frame deletions; 2 substitution
- Prediction scores: 592 variants have prediction scores (82% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: mitochondrial trifunctional protein deficiency 2, mitochondrial trifunctional protein deficiency, mitochondrial trifunctional protein deficiency 1, long chain 3-hydroxyacyl-CoA dehydrogenase deficiency, neurodegenerative disease, alcohol drinking, gastrointestinal disease, complication, hereditary disease, metabolic acidosis, renal tubular acidosis, rickets.
Protein structure and variant hotspots
- Protein features: 14 post-translational modification sites.
- PTM context: 13 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable HADHB variants
Examples include M1V, p.Met1 Thr2insAla, p.Thr2dup, T2I, p.Thr2 Ile3insAla, T2A, T2N, T2S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs763333945, ClinGen CA1560046, ClinVar RCV000485249, ClinVar RCV003766657, MetaLR 0.85, MetaSVM 0.70, Pathogenic, not provided; Mitochondrial trifunctional protein deficiency
- p.Met1 Thr2insAla, rs1064793144, gnomAD 2-26254257-G-GGCT, CADD 19.60
- p.Thr2dup, gnomAD 2-26254257-G-GACA, CADD 19.60
- T2I (p.Thr2Ile), gnomAD 2-26254257-G-GAT, CADD 28.40
- p.Thr2 Ile3insAla, rs869300499, gnomAD 2-26254258-A-ACTG, CADD 17.10
- T2A (p.Thr2Ala), gnomAD 2-26254258-A-G, REVEL 0.24, CADD 14.20
- T2N (p.Thr2Asn), gnomAD 2-26254259-C-A, REVEL 0.33, CADD 21.60
- T2S (p.Thr2Ser), gnomAD 2-26261024-A-T, CADD 6.59
- T2K (p.Thr2Lys), gnomAD 2-26261025-C-A, CADD 5.43
- T2T (p.Thr2Thr), gnomAD 2-26261026-A-G, CADD 8.53
- I3L (p.Ile3Leu), ExAC rs766553932, TOPMed rs766553932, gnomAD rs766553932
- I3T (p.Ile3Thr), Ensembl rs1671523128
- I3V (p.Ile3Val), ExAC rs766553932, TOPMed rs766553932, gnomAD rs766553932, REVEL 0.20, CADD 14.10
- p.Ile3delinsThrVal, rs1258501693, gnomAD 2-26254261-A-ACTG, CADD 26.10
- I3I (p.Ile3Ile), rs1671523247, gnomAD 2-26254263-C-A, CADD 7.61
- L4P (p.Leu4Pro), gnomAD 2-26254262-T-TAC, CADD 26.30
- L4T (p.Leu4Thr), gnomAD 2-26254262-T-TAA, CADD 26.30
- L4L (p.Leu4Leu), gnomAD 2-26254264-T-C, CADD 7.01
- L4M (p.Leu4Met), gnomAD 2-26254264-T-A, REVEL 0.36, CADD 22.80
- L4S (p.Leu4Ser), gnomAD 2-26254265-T-C, REVEL 0.46, CADD 24.20
- L4F (p.Leu4Phe), gnomAD 2-26254266-G-T, REVEL 0.35, CADD 23.70
- L4V (p.Leu4Val), gnomAD 2-26261027-C-G, CADD 1.84
- T5S (p.Thr5Ser), gnomAD 2-26254267-A-T, REVEL 0.24, CADD 17.00
- T5A (p.Thr5Ala), gnomAD 2-26254267-A-G, REVEL 0.29, CADD 17.50
- T5N (p.Thr5Asn), gnomAD 2-26254268-C-A, REVEL 0.24, CADD 14.80
- T5I (p.Thr5Ile), gnomAD 2-26254268-C-T, REVEL 0.27, CADD 16.50
- T5T (p.Thr5Thr), gnomAD 2-26254269-T-C, CADD 8.06
- Y6T (p.Tyr6Thr), gnomAD 2-26254268-CT-C, CADD 23.10
- Y6H (p.Tyr6His), gnomAD 2-26254270-T-C, REVEL 0.16, CADD 15.20
- Y6S (p.Tyr6Ser), gnomAD 2-26254270-TA-T, CADD 14.10
- Y6F (p.Tyr6Phe), gnomAD 2-26254271-A-T, REVEL 0.16, CADD 1.16
- Y6C (p.Tyr6Cys), gnomAD 2-26254271-A-G, REVEL 0.22, CADD 7.27
- Y6Y (p.Tyr6Tyr), rs759720030, gnomAD 2-26254272-C-T, CADD 0.45
- Y6* (p.Tyr6Ter), gnomAD 2-26254272-C-A, CADD 25.00
- Y6N (p.Tyr6Asn), gnomAD 2-26261048-T-A, CADD 4.49
- P7L (p.Pro7Leu), gnomAD rs866708381, REVEL 0.31, CADD 15.90
- P7R (p.Pro7Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P7S (p.Pro7Ser), gnomAD 2-26254273-C-T, REVEL 0.28, CADD 1.22
- P7T (p.Pro7Thr), gnomAD 2-26254273-C-A, REVEL 0.29, CADD 0.93
- P7H (p.Pro7His), gnomAD 2-26254274-C-A, REVEL 0.30, CADD 19.10
- P7P (p.Pro7Pro), gnomAD 2-26254275-C-A, CADD 1.45
- F8L (p.Phe8Leu), rs775035854, gnomAD 2-26254271-AC-A, CADD 12.20
- F8S (p.Phe8Ser), gnomAD 2-26254277-T-C, REVEL 0.50, CADD 19.40
- F8F (p.Phe8Phe), gnomAD 2-26254278-T-C, CADD 1.34
- K9E (p.Lys9Glu), gnomAD 2-26254279-A-G, REVEL 0.39, CADD 22.30
- K9* (p.Lys9Ter), gnomAD 2-26254279-A-T, CADD 35.00
- K9R (p.Lys9Arg), gnomAD 2-26254280-A-G, REVEL 0.28, CADD 8.26
- N10H (p.Asn10His), NCI-TCGA Cosmic COSV5854, cosmic curated COSV58545, Variant assessed as somatic; moderate impact.
- N10K (p.Asn10Lys), gnomAD 2-26254278-T-TA, CADD 23.70
- N10S (p.Asn10Ser), gnomAD 2-26254278-TAA-T, CADD 23.60
- N10I (p.Asn10Ile), gnomAD 2-26254278-TA-T, CADD 23.60
- N10D (p.Asn10Asp), gnomAD 2-26254282-A-G, REVEL 0.26, CADD 16.40
- L11P (p.Leu11Pro), rs973465081, ClinGen CA44371778, ClinVar RCV003849663, TOPMed rs973465081, REVEL 0.62, CADD 23.90, Uncertain significance, Mitochondrial trifunctional protein deficiency
- L11I (p.Leu11Ile), gnomAD 2-26254285-C-A, REVEL 0.29, CADD 14.50
- L11L (p.Leu11Leu), gnomAD 2-26254287-T-C, CADD 5.67
- L11F (p.Leu11Phe), gnomAD 2-26261042-C-T, CADD 7.01
- L11H (p.Leu11His), gnomAD 2-26261043-T-A, CADD 1.89
- P12A (p.Pro12Ala), TOPMed rs1671523943, gnomAD rs1671523943, REVEL 0.29, CADD 12.70
- P12L (p.Pro12Leu), NCI-TCGA TCGA novel, REVEL 0.33, CADD 10.20, Variant assessed as somatic; moderate impact.
- P12S (p.Pro12Ser), gnomAD 2-26254288-C-T, REVEL 0.26, CADD 14.20
- P12T (p.Pro12Thr), gnomAD 2-26254288-C-A, REVEL 0.30, CADD 17.50
- P12H (p.Pro12His), gnomAD 2-26254289-C-A, REVEL 0.33, CADD 18.30
- P12P (p.Pro12Pro), gnomAD 2-26254290-C-A, CADD 0.33
- T13L (p.Thr13Leu), rs760042114, gnomAD 2-26254287-TC-T, CADD 23.10
- T13S (p.Thr13Ser), gnomAD 2-26254291-A-T, REVEL 0.16, CADD 1.13
- T13A (p.Thr13Ala), gnomAD 2-26254291-A-G, REVEL 0.17, CADD 3.12
- T13I (p.Thr13Ile), gnomAD 2-26254292-C-T, REVEL 0.23, CADD 0.23
- T13N (p.Thr13Asn), gnomAD 2-26254292-C-A, REVEL 0.18, CADD 0.12
- T13T (p.Thr13Thr), gnomAD 2-26254293-T-C, CADD 1.91
- A14H (p.Ala14His), gnomAD 2-26254292-CT-C, CADD 15.10
- A14T (p.Ala14Thr), gnomAD 2-26254294-G-A, REVEL 0.20, CADD 0.22
- A14E (p.Ala14Glu), gnomAD 2-26254295-C-A, REVEL 0.26, CADD 14.30
- A14V (p.Ala14Val), gnomAD 2-26254295-C-T, REVEL 0.23, CADD 16.80
- A14A (p.Ala14Ala), gnomAD 2-26254296-A-G, CADD 7.66
- A14S (p.Ala14Ser), gnomAD 2-26261063-G-T, CADD 15.70
- S15* (p.Ser15Ter), NCI-TCGA TCGA novel, CADD 35.00, Variant assessed as somatic; high impact.
- S15T (p.Ser15Thr), gnomAD 2-26254297-T-A, REVEL 0.24, CADD 15.60
- S15P (p.Ser15Pro), gnomAD 2-26254297-T-C, REVEL 0.42, CADD 18.70
- S15S (p.Ser15Ser), gnomAD 2-26254299-A-G, CADD 8.07
- S15W (p.Ser15Trp), gnomAD 2-26261030-GTT-G, CADD 6.53
- S15F (p.Ser15Phe), gnomAD 2-26261034-C-T, CADD 7.46
- S15Y (p.Ser15Tyr), gnomAD 2-26261034-C-A, CADD 6.07
- K16T (p.Lys16Thr), ExAC rs768017278, gnomAD rs768017278, REVEL 0.21, CADD 16.70
- K16N (p.Lys16Asn), gnomAD 2-26254298-CA-C, CADD 24.10
- K16E (p.Lys16Glu), gnomAD 2-26254300-A-G, REVEL 0.21, CADD 6.94
- K16R (p.Lys16Arg), gnomAD 2-26254301-A-G, REVEL 0.24, CADD 16.70
- K16K (p.Lys16Lys), rs1478976137, gnomAD 2-26254302-A-G, CADD 8.73
- W17* (p.Trp17Ter), Ensembl rs920297938, CADD 38.00, Pathogenic
- W17L (p.Trp17Leu), TOPMed rs1671524499, Uncertain significance, not provided
- W17R (p.Trp17Arg), gnomAD 2-26254303-T-C, REVEL 0.54, CADD 21.80
- W17C (p.Trp17Cys), rs764471823, gnomAD 2-26261056-G-C, CADD 8.52
- A18T (p.Ala18Thr), gnomAD rs1671524697, REVEL 0.27, CADD 16.40
- A18V (p.Ala18Val), rs1313401825, TOPMed rs1313401825, gnomAD rs1313401825, REVEL 0.28, CADD 20.30, Variant assessed as somatic; moderate impact.
- A18P (p.Ala18Pro), gnomAD 2-26254303-TG-T, CADD 27.60
- A18D (p.Ala18Asp), gnomAD 2-26254307-C-A, REVEL 0.51, CADD 22.70
- A18A (p.Ala18Ala), gnomAD 2-26254308-C-A, CADD 7.27
- L19F (p.Leu19Phe), gnomAD 2-26254309-C-T, REVEL 0.41, CADD 16.00
- L19I (p.Leu19Ile), gnomAD 2-26254309-C-A, REVEL 0.22, CADD 14.40
- L19H (p.Leu19His), gnomAD 2-26254310-T-A, REVEL 0.50, CADD 23.20
- L19R (p.Leu19Arg), gnomAD 2-26254310-T-G, REVEL 0.59, CADD 23.20
- L19P (p.Leu19Pro), gnomAD 2-26254310-T-C, REVEL 0.65, CADD 23.30
- L19L (p.Leu19Leu), gnomAD 2-26254311-C-T, CADD 9.52
- R20I (p.Arg20Ile), NCI-TCGA Cosmic COSV5854, cosmic curated COSV58548, Variant assessed as somatic; moderate impact.
- R20G (p.Arg20Gly), gnomAD 2-26254312-A-G, REVEL 0.37, CADD 16.70
- R20S (p.Arg20Ser), gnomAD 2-26254314-A-T, REVEL 0.48, CADD 21.30
- F21V (p.Phe21Val), ExAC rs756430935, gnomAD rs756430935, REVEL 0.52, CADD 21.90
- S22C (p.Ser22Cys), rs1671530038, ClinGen CA346101339, ClinVar RCV001317759, TOPMed rs1671530038, REVEL 0.27, CADD 14.00, Uncertain significance, Mitochondrial trifunctional protein deficiency
- S22P (p.Ser22Pro), ExAC rs764430901, gnomAD rs764430901, REVEL 0.39, CADD 16.40
- S22Y (p.Ser22Tyr), gnomAD 2-26254430-C-A, REVEL 0.36, CADD 13.30
- S22S (p.Ser22Ser), gnomAD 2-26254431-C-A, CADD 4.31
- I23M (p.Ile23Met), ExAC rs764494047, gnomAD rs764494047, REVEL 0.16, CADD 9.30
- I23V (p.Ile23Val), rs761139282, ClinGen CA1560076, ClinVar RCV003347289, ExAC rs761139282, REVEL 0.28, CADD 0.00, Likely benign, Inborn genetic diseases
- I23I (p.Ile23Ile), gnomAD 2-26254434-A-C, CADD 6.05
- I23T (p.Ile23Thr), gnomAD 2-26261061-T-C, CADD 1.41
- R24* (p.Arg24Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, Variant assessed as somatic; high impact.
- R24K (p.Arg24Lys), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, Variant assessed as somatic; moderate impact.
- R24R (p.Arg24Arg), gnomAD 2-26254435-A-C, CADD 10.70
- P25L (p.Pro25Leu), rs1434038212, ClinGen CA346101421, ClinVar RCV001949042, TOPMed rs1434038212, REVEL 0.36, CADD 20.90, Uncertain significance, Mitochondrial trifunctional protein deficiency
- P25T (p.Pro25Thr), gnomAD 2-26254438-C-A, REVEL 0.30, CADD 11.00
- P25P (p.Pro25Pro), gnomAD 2-26254440-T-C, CADD 9.78
- L26L (p.Leu26Leu), gnomAD 2-26254443-G-A, CADD 11.00
- S27T (p.Ser27Thr), rs1295452279, ClinGen CA346101477, ClinVar RCV002671736, TOPMed rs1295452279, REVEL 0.41, CADD 22.80, Uncertain significance, Mitochondrial trifunctional protein deficiency
- S27G (p.Ser27Gly), gnomAD 2-26254444-A-G, REVEL 0.41, CADD 22.90
- S27R (p.Ser27Arg), gnomAD 2-26254446-C-A, REVEL 0.62, CADD 23.40
- S27S (p.Ser27Ser), gnomAD 2-26254446-C-T, CADD 13.60
- S29Y (p.Ser29Tyr), gnomAD 2-26254451-C-A, REVEL 0.58, CADD 22.30
- S29S (p.Ser29Ser), rs754238881, gnomAD 2-26254452-C-T, CADD 8.18
- S30P (p.Ser30Pro), gnomAD 2-26254452-CT-C, CADD 25.60
- S30S (p.Ser30Ser), gnomAD 2-26254455-C-A, CADD 10.70
- Q31* (p.Gln31Ter), ExAC rs764825824, gnomAD rs764825824, CADD 37.00, Uncertain significance
- Q31E (p.Gln31Glu), rs764825824, ClinGen CA1560081, ClinVar RCV003064886, ExAC rs764825824, REVEL 0.32, CADD 17.40, Uncertain significance, Mitochondrial trifunctional protein deficiency
- Q31S (p.Gln31Ser), gnomAD 2-26254453-TC-T, CADD 25.80
- Q31K (p.Gln31Lys), gnomAD 2-26254456-C-A, REVEL 0.46, CADD 18.30
- Q31Q (p.Gln31Gln), gnomAD 2-26254458-G-A, CADD 9.00
- L32P (p.Leu32Pro), ExAC rs779498186, TOPMed rs779498186, gnomAD rs779498186, REVEL 0.51, CADD 22.90, Uncertain significance, Inborn genetic diseases
- L32V (p.Leu32Val), ExAC rs757859545, gnomAD rs757859545
- L32I (p.Leu32Ile), gnomAD 2-26254459-C-A, REVEL 0.32, CADD 17.90
- R33* (p.Arg33Ter), rs752264795, ClinGen CA1560084, ClinVar RCV001389145, ClinVar RCV004570969, CADD 35.00, Pathogenic
- R33G (p.Arg33Gly), ExAC rs752264795, TOPMed rs752264795, gnomAD rs752264795, Pathogenic
- R33Q (p.Arg33Gln), rs372980146, ClinGen CA1560085, cosmic curated COSV58545, ClinVar RCV001863809, REVEL 0.16, CADD 4.02, Uncertain significance, not provided; Mitochondrial trifunctional protein deficiency
- R33R (p.Arg33Arg), gnomAD 2-26254462-C-A, CADD 11.30
- A34G (p.Ala34Gly), cosmic curated COSV10050, gnomAD rs1671531344, REVEL 0.26, CADD 22.40
- A34T (p.Ala34Thr), gnomAD 2-26254465-G-A, REVEL 0.17, CADD 19.10
- A34V (p.Ala34Val), gnomAD 2-26254466-C-T, REVEL 0.32, CADD 22.50
- A34D (p.Ala34Asp), gnomAD 2-26254466-C-A, REVEL 0.36, CADD 21.20
- A34A (p.Ala34Ala), gnomAD 2-26254467-T-C, CADD 11.60
- A35G (p.Ala35Gly), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, Variant assessed as somatic; moderate impact.
- A35V (p.Ala35Val), Ensembl rs1213140579, REVEL 0.34, CADD 17.70
- A35T (p.Ala35Thr), gnomAD 2-26254468-G-A, REVEL 0.22, CADD 18.40
- A35D (p.Ala35Asp), gnomAD 2-26254469-C-A, REVEL 0.40, CADD 21.80
- A35A (p.Ala35Ala), gnomAD 2-26254470-C-A, CADD 6.36
- P36L (p.Pro36Leu), ESP rs376096533, TOPMed rs376096533, gnomAD rs376096533, REVEL 0.34, CADD 23.60
- P36S (p.Pro36Ser), rs781309147, ClinGen CA1560086, ClinVar RCV003089487, ExAC rs781309147, REVEL 0.26, CADD 10.90, Uncertain significance, Mitochondrial trifunctional protein deficiency
- P36T (p.Pro36Thr), cosmic curated COSV10050, ExAC rs781309147, TOPMed rs781309147, gnomAD rs781309147, REVEL 0.25, CADD 9.32, Uncertain significance
- P36Q (p.Pro36Gln), gnomAD 2-26254468-GC-G, CADD 23.80
- P36A (p.Pro36Ala), gnomAD 2-26254471-C-G, REVEL 0.20, CADD 8.26
- P36P (p.Pro36Pro), gnomAD 2-26254473-A-G, CADD 22.90
- A37D (p.Ala37Asp), NCI-TCGA TCGA novel, REVEL 0.53, CADD 18.70, Variant assessed as somatic; moderate impact.
- A37P (p.Ala37Pro), rs201078199, ClinGen CA1560087, ClinVar RCV003072125, ClinVar RCV003481385, REVEL 0.49, CADD 35.00, Uncertain significance, not provided; Mitochondrial trifunctional protein deficiency
- A37S (p.Ala37Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A37T (p.Ala37Thr), ESP rs201078199, ExAC rs201078199, TOPMed rs201078199, gnomAD rs201078199, REVEL 0.40, CADD 34.00, Uncertain significance
- A37V (p.Ala37Val), TOPMed rs1671938221, gnomAD rs1671938221, REVEL 0.41, CADD 21.40
- A37A (p.Ala37Ala), rs1574650470, gnomAD 2-26263381-T-C, CADD 1.00
- V38F (p.Val38Phe), rs553040477, ClinGen CA1560099, ClinVar RCV002756126, 1000Genomes rs553040477, REVEL 0.23, CADD 9.81, Uncertain significance, Mitochondrial trifunctional protein deficiency
- V38A (p.Val38Ala), gnomAD 2-26261031-T-C, CADD 8.67
- V38I (p.Val38Ile), gnomAD 2-26263382-G-A, REVEL 0.19, CADD 6.34
- V38V (p.Val38Val), gnomAD 2-26263384-C-A, CADD 1.89
- Q39* (p.Gln39Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, Variant assessed as somatic; high impact.
- Q39R (p.Gln39Arg), ExAC rs765893367, gnomAD rs765893367, REVEL 0.52, CADD 19.90
- Q39K (p.Gln39Lys), gnomAD 2-26263385-C-A, REVEL 0.42, CADD 16.20
- Q39Q (p.Gln39Gln), gnomAD 2-26263387-G-A, CADD 7.39
- T40S (p.Thr40Ser), gnomAD 2-26263388-A-T, REVEL 0.27, CADD 14.40
- T40N (p.Thr40Asn), gnomAD 2-26263389-C-A, REVEL 0.36, CADD 16.80
- K41E (p.Lys41Glu), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10050, REVEL 0.43, CADD 20.20, Variant assessed as somatic; moderate impact.
- T42M (p.Thr42Met), ExAC rs751072011, TOPMed rs751072011, gnomAD rs751072011, REVEL 0.25, CADD 18.80
- T42S (p.Thr42Ser), TOPMed rs1191272205, gnomAD rs1191272205, REVEL 0.26, CADD 0.93
- T42N (p.Thr42Asn), rs1477343493, gnomAD 2-26263390-C-CA, CADD 25.30
- T42T (p.Thr42Thr), gnomAD 2-26263396-G-C, CADD 0.37
- K43K (p.Lys43Lys), rs2147809837, gnomAD 2-26263399-G-A, CADD 8.85
- K44N (p.Lys44Asn), NCI-TCGA TCGA novel, REVEL 0.53, CADD 22.80, Variant assessed as somatic; moderate impact.
Public HADHB analysis runs
- HADHB analysis run — HADHB (725 variants) — completed 2026-08-22